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license (http://creativeimpairment (MCI) to Alzheimer’s disease. Cilostazol is a selective type-3 phosphodiesterase inhib-
itor that ameliorates accumulation of amyloid-b and has prevented cognitive decline in rodent
models. Furthermore, cilostazol is known to suppress platelet aggregation, protect vascular endo-
thelia, dilate vessels, and increase cerebral blood flow. Beneficial effects have also been shown in
observational cohort studies, demonstrating the need for a prospective clinical trial.
Methods: The Cilostazol for prevention of COnversion fromMCI to Dementia (COMCID) study is a
double-blind, randomized phase II study of patients with MCI. Participants will receive cilostazol or
placebo for 96 weeks. The primary objective is to evaluate whether cilostazol slows down cognitive
decline measured by the Mini-Mental State Examination. Secondary objectives are assessing time to
conversion fromMCI to dementia and assessing incremental changes in several psychological assess-
ment scales.
Discussion: The COMCID trial will identify the therapeutic potential of cilostazol. This trial, which
is based on a drug repositioning strategy, may aid the development of a neurovascular treatment for
neurocognitive disorders.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Cilostazol; Clearance; Clinical trial; Drug repositioningonal protocol number: TRINEU1321) was registered
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Epidemiologic investigations have proposed that strict
control of vascular risk factors is an effective preventative
strategy for dementia because of the close relationship be-
tween Alzheimer’s disease (AD) and cerebrovascular dis-
ease (CVD) [1]. AD is thought to result from an imbalance
between production and clearance of amyloid-b (Ab), andimer’s Association. This is an open access article under the CC BY-NC-ND
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failure [2]. Decreased cerebral blood flow is closely related
to CVD and seems to modulate amyloid precursor protein
cleavage enzymes, such as b- and g-secretase, leading to
increased Ab production [3]. A large proportion of Ab clear-
ance takes place through vascular-mediated systems, via
active transport across the blood-brain barrier, perivascular
lymphatic and paravascular glymphatic drainage networks,
all of which can be disturbed by CVD [4]. Familial cases
of AD may be, at least in part, attributable to excess Ab pro-
duction. However, insufficient Ab clearance is more crucial
in cases of sporadic AD [5]. Therefore, researchers have
increasingly sought to address the problem of Ab elimina-
tion in AD therapy [6].
The vasoactive drug cilostazol inhibits type-3 phospho-
diesterase and is expected to promote Ab clearance. In ro-
dent models exhibiting Ab accumulation, administering
cilostazol prevented Ab deposition and improved cognitive
function by increasing hemodynamic reserve and facili-
tating perivascular drainage of Ab [7]. The brain paren-
chyma is devoid of a conventional lymphatic system,
although the lymphatic vessels were recently found to exist
along meningeal vessels [8]. Interstitial fluid and solutes,
including Ab, are cleared through a perivascular drainage
route, which is formed by two basement membranes in
the walls of cerebral arteries [9]. Cilostazol was found to
facilitate this clearance system in vivo [7]. Furthermore,
experimental studies indicate that cilostazol reduces Ab
production and suppresses tau phosphorylation by inhibit-
ing glycogen synthase kinase 3b, via enhancement of
casein kinase 2a/silent information regulator 1 phosphory-
lation, in vitro [7,10,11]. Whether such effects are viable in
AD and mild cognitive impairment (MCI) patients is not
yet clear as only a minor fraction of cilostazol passes
through the blood-brain barrier [12].
Cilostazol is currently prescribed in Asia, Europe, and the
United States as an antiplatelet drug for symptomatic treat-
ment of peripheral arterial disease. It is also used in Asia
for the secondary prevention of ischemic stroke. The second
Cilostazol Stroke Prevention Study for patients with cerebral
infarction showed that hemorrhagic stroke was significantly
less frequent with cilostazol treatment than with aspirin
[13,14]. The prevention of cerebral hemorrhage may be
explained by its protective effects on vascular endothelial
cells [15]. Furthermore, cilostazol is known to dilate blood
vessels, leading to increased cerebral blood flow [16]. These
results suggest that cilostazol could be suitable for patients
with both AD neurodegeneration and CVD.
Favorable effects have been reported in observational
clinical studies, which demonstrated efficacy of cilostazol
in patients with MCI [17], donepezil-treated patients with
clinically probable AD [18,19], and AD with CVD [20].
These results have thus highlighted the need for a compre-
hensive prospective cohort study to determine whether
cilostazol helps preserve cognitive function in patients
with MCI.2. Methods
2.1. Study design
The investigator-initiated Cilostazol for prevention of
COnversion from MCI to Dementia (COMCID) trial is a
double-blind, placebo-controlled, randomized early phase
II study aimed at evaluating the efficacy and safety of cilos-
tazol in patients with MCI (Fig. 1). Two hundred MCI pa-
tients will be randomly assigned to cilostazol or placebo
control arms. The allocation ratio is 1 to 1.
2.2. Study objectives
The primary objective of the study is to evaluate the efficacy
of cilostazol in patients with MCI in preserving cognitive
function measured by the Mini-Mental State Examination
(MMSE). The secondary objectives are to evaluate the efficacy
of cilostazol in assessing time to conversion fromMCI to “all-
cause dementia,” as well as changes in the Clinical Dementia
Rating–Sum of Boxes (CDR-SB), Alzheimer’s Disease
Assessment Scale–cognitive sub-scale (ADAS-cog) 14,
Wechsler Memory Scale-Revised (WMS-R) Logical Memory
part II, and Alzheimer’s Disease Cooperative Study–Mild
Cognitive Impairment–Activities of Daily Living
(ADCS-MCI-ADL).Another secondary objective is to explore
the efficacy of cilostazol on the hippocampal atrophy,
measured by brain magnetic resonance imaging (MRI).
2.3. Enrollment
MCI patients are recruited from 15 high-volume centers
for patients with dementia in Japan. Potential participants
will undergo screening assessment to confirm eligibility
(Fig. 2). Blood examinations and MRI investigation for con-
firming eligibility will not be scheduled in the COMCID trial
as only MCI patients who have undergone sufficient labora-
tory tests for clinical purposes before informed consent about
this trial can participate. These laboratory examinations are
routinely performed in all trial sites. Pure vascular MCI pa-
tients are ineligible, whereas patients with coincidental cere-
bral infarctions or white matter changes not likely to wholly
explain their cognitive dysfunction are eligible. Based on the
core clinical criteria stated in the National Institute on Aging-
Alzheimer’s Association classification [21], MCI is diag-
nosed when individuals meet the following criteria:
 cognitive concern reflecting a change in cognition re-
ported by the patient, informant, or clinician
 objective evidence of impairment in one or more
cognitive domains
 preservation of independence in functional abilities
 not demented
In addition, MMSE scores between 22 and 28 (inclusive)
and CDR scores of 0.5 are required for provisional registra-
tion (Fig. 1). Results fromMMSE and CDR will be reviewed
by an independent central psychological review board. If the
patient is judged to be eligible, the review board will submit
Fig. 1. Study design for the COMCID trial (ClinicalTrials.gov NCT02491268, UMIN Clinical Trials Registry UMIN000017764). (A) Schematic flow diagram
of the enrollment process. (B) The schedule of interventions and assessments. MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating;
ADAS-Cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; WMS-R, Wechsler Memory Scale-Revised; TMT, Trail making test; FCSRT, Free
and Cued Selective Reminding Test; ADCS-MCI-ADL, Alzheimer’s Disease Cooperative Study–Mild Cognitive Impairment–Activities of Daily Living;
MRI, magnetic resonance imaging; AEs, adverse events.
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completed. The reviewed MMSE and CDR scores will be
used for baseline assessment data; baseline CDR scores are
0.5 in all the enrolled participants. Then, ADAS-cog 14,
WMS-R Logical Memory part II, and ADCS-MCI-ADL
will be performed for baseline assessment. MRI assessments
are planned at 4 of the 15 participating institutions.
2.4. Allocation and blinding
Registered patients will be randomly assigned to cilostazol
or control arms. The assignment method is minimization, and
the stratification factors are age (75 years), sex, education
(12 years), and institution. The randomization will be per-
formed by computer-generated random allocation treatment
codes, with patients and physicians blinded to the therapy,
and the randomization list will be kept by an independent
investigator not involved in the care or assessment of the pa-
tients, or data collection and analysis. Emergency unblinding
will be performed only when the principal investigators and
the COMCID trial coordinating committee admit the neces-
sity to uncover the assigned intervention in order to treat
any potential adverse events (AEs) in participants.
2.5. Interventions
Cilostazol and placebo are provided by Otsuka Pharma-
ceutical Company, Japan. Participants assigned to the cilos-tazol arm will receive one 50-mg tablet of cilostazol twice a
day for 96 weeks. Those assigned to the control arm will
receive one placebo tablet twice a day for 96 weeks. If
dose reduction resulting from any AEs is needed, the proto-
col treatment will be discontinued. The study physicians will
maintain the drug inventory record of supplied, received,
dispensed, destroyed, and returned medication.
2.6. Concomitant medications
The protocol treatment will be stopped when antidemen-
tia drugs and anticoagulants are started; when the patient is
treated for schizophrenia, major depression, or bipolar disor-
der; or when major tranquilizers are administered against
persistent delirium or behavioral and psychological symp-
toms of dementia. The use of minor tranquilizers, including
benzodiazepines for neurosis or insomnia, is permitted in the
trial period. Diet therapy, rehabilitation, and any medica-
tions other than prohibited medications will not be restricted.
2.7. Psychological examination
Only psychologists or medical doctors who complete
training programs and pass the qualifying examinations
will be permitted to carry out the cognitive testing outlined
in this study. All records from the psychological examina-
tions, including patients’ and partners’ answers, as well as
examiners’ records, will be collected by the independent
Fig. 2. Eligibility criteria.MCI, mild cognitive impairment; NIA/AA,National Institute onAging-Alzheimer’s Association;MRI,magnetic resonance imaging;
HbA1c, glycated haemoglobin (A1c); AD, Alzheimer’s Disease.
S. Saito et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 250-257 253central psychological review board. The board will comprise
one neurologist, one psychiatrist, and three psychologists.
CDR is authorized by Washington University, and grading
is affirmed by consensus of the board members.
2.8. The imaging study
Hippocampal volume assessment will be performed with
a 3.0-T MRI scanner (Skyra, TIM Trio, or Verio; Siemens
AG, Germany). Two T1-weighted MRI scans will be
collected using a three-dimensional sagittal magnetization-
prepared rapid gradient echo sequence, according to the
Alzheimer’s Disease Neuroimaging Initiative 3.0-T MRI
protocol (http://adni.loni.usc.edu/methods/mri-analysis/
mri-acquisition/). Imaging data will be sent to the central
evaluation committee, comprising four neuroradiologists.Automated hippocampal volumetry will be carried out using
FreeSurfer software, version 5.3 [22]. Previous reports
showed that these analyzing methods could generate consis-
tent outcome measures for the hippocampal volume with
less than 4% of reproducibility errors, even when several
MRI scanners from different vendors were used [23,24].
Fluid-attenuated inversion recovery images for assessing
white matter hyperintensities and T2*-weighted images for
detecting cerebral microbleeds will be also planned.
2.9. Data collection
Web-based electronic data capture system will be used
to collect clinical data obtained from patient medical re-
cords. Laboratory data and data from the independent cen-
tral psychological review board and the central evaluation
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before being finally integrated. The persons assigned to
data management will perform quality control at each
step of data handling to ensure the reliability of all data
related to the study.2.10. Statistical analysis
The sample size was determined by feasibility but sub-
stantial enough to perform the primary analysis. Our preced-
ing investigation for MCI patients treated with cilostazol
showed that the annual changes of total MMSE scores
were about60 points within approximately 2 years of obser-
vation period [17], whereas Petersen et al. reported that the
MMSE score changes in MCI patients were about 21.0
point/y [25]. With 90% power, a two-tailed type I error
rate of 5%, and an estimate of the population standard devi-
ation of 3.7 for changes in total MMSE scores, this sample
size can detect a statistically significant difference if the ef-
fect size is more than 1.72 between two treatments. The stan-
dard deviation referred to the Alzheimer’s Disease
Neuroimaging Initiative study and our preceding investiga-
tion [17].
We will analyze a full analysis set, defined as data ob-
tained from the registered patients who will receive at least
a part of the assigned treatment. However, patients found
to be noneligible after the registration should be excluded
from the full analysis set.
To evaluate the improvement of the cognitive function by
the treatments, the changes in total MMSE scores between
the baseline and 96 weeks after starting protocol treatment
will be tested by t test or Wilcoxon rank sum test. The COM-
CID trial will judge the efficacy of cilostazol using this anal-
ysis. Furthermore, the scores at baseline, 24, 48, 72, and
96 weeks will be analyzed with a mixed-model repeated
measures by considering treatments, gender, and time as
fixed effects and patient! time as a random effect.
The time to convert from MCI to “all-cause dementia”
will be analyzed using suitable survival analysis approaches,
such as Kaplan-Meier with log-rank tests and Cox propor-
tional hazard models. If patients are diagnosed with demen-
tia, the protocol treatment will cease.
Incremental changes in CDR-SB, ADAS-cog 14, WMS-
R Logical Memory part II, and ADCS-MCI-ADL will be
analyzed with the same procedure as MMSE. Hippocampal
volume change on MRI over time will be compared between
cilostazol and control arms statistically.2.11. Exploratory analysis
The followings issues will be evaluated in an exploratory
analysis:
 incremental changes in scores from Trail Making Test
Part A and Part B
 incremental changes in scores from the Free and Cued
Selective Reminding Test incremental changes in the serum levels of albumin-Ab
complexes [26]2.12. Ethical matters
This study has been approved by the National Cerebral
and Cardiovascular Center and other institutional review
boards. All procedures will comply with the International
Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use “Guide-
line for Good Clinical Practice” and its revised ministerial
ordinances/operational notifications in Japan.
Written informed consent will be obtained from all pa-
tients before enrollment. If the written informed consent
form is revised, the study physicians will explain the proced-
ure again, revise the written informed consent form, and
obtain the subject’s voluntary consent for continuation of
participation.2.13. Safety profile
If an AE occurs, the study physicians will treat the patient
adequately in terms of safety and report the details of the
event. If a severe AE (SAE) occurs, the study physicians
and principal investigator must report it to the head of insti-
tution and the COMCID trial coordinating committee within
24 hours. The coordinating committee should decide
whether the SAE needs 7-day, 15-day (Japan’s Pharmaceu-
tical Affairs Law, Enforcement Regulations, Article 273),
or no reporting. If submission of those reports is required,
the principal investigator and the coordinating committee
should complete the prespecified submission form and sub-
mit it to the head of institution and Japan’s Pharmaceuticals
and Medical Devices Agency. The coordinating committee
should inform of the safety information to the other site in-
vestigators and the pharmaceutical company. The other site
investigators should submit the reports to the head of institu-
tion as soon as possible.
If the SAE is caused by protocol treatment, follow-up will
be continued until recovery. The patient will be compensated
for any study-related injuries by insurance.2.14. Data-monitoring committee
For safety monitoring, an independent data-monitoring
committee (DMC) will discuss the safety-related end points,
including SAEs. The DMC consists of a clinical physician,
neurologist, cardiologist, and an expert statistician. If an
SAE occurs, the COMCID trial coordinating committee
should promptly report the safety information to the member
of DMC. The DMC will be held by the initiative of the com-
mittee member in accordance with “Standard Operating
Procedure: Operation of a Data Monitoring Committee.”
The DMC can request revision of the study protocol or
stop the trial. When revision of the study protocol is pro-
posed by the DMC, the principal investigators and the
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to the head of institution and obtain approval from the insti-
tutional review board.2.15. Auditing
The auditors (A.T., M.A., R.U., K.K., and T.K., Office of
Clinical Quality Assurance, Otsuka Pharmaceutical Com-
pany, Japan) will evaluate whether the conduct of this study
is in compliance with the Guideline for Good Clinical Prac-
tice and study protocol. Auditing is distinguished from
routine monitoring and quality control of the study, which
is performed from the standpoint of an outsider as part of
quality assurance activities. Two contract research organiza-
tions and 4 of the 15 participating institutions where many
patients are expected to be registered will be audited three
times: before, during, and after this trial.3. Discussion
This COMCID trial is based upon a drug repositioning
strategy, a process aimed at discovering new therapeutic
drugs from existing drugs in a clinical setting [27]. The es-
tablished safety profile possesses many advantages over de
novo therapy, contributing to this phase II trial without any
additional pharmacokinetic or toxicologic investigations.
Drug repositioning is an attractive and timely drug develop-
ment strategy [27].
The target patient population in this trial is not limited to
MCI due to AD or presumed AD.MCI diagnosis is not based
on the research criteria but the core clinical criteria in the
National Institute on Aging-Alzheimer’s Association
classification [21], which is equivalent to what the Diag-
nostic and Statistical Manual of Mental Disorders, fifth edi-
tion, terms “mild neurocognitive disorder” [28]. AD and
vascular dementia, the two most common causes of demen-
tia, represent two ends in a spectrum of disorders. Most pa-
tients exhibit varying degrees of neurodegenerative and
vascular pathologies between these extremes [29], providing
a rationale for the use of cilostazol in MCI in the general
population [30].
Investigational therapy is 100 mg/d of cilostazol adminis-
tration for 96 weeks, whereas 200 mg/d of cilostazol is
commonly used for secondary prevention of ischemic
strokes. Our retrospective cohort study showed that cilosta-
zol significantly improved MMSE scores, compared with
control groups [17]. The mean follow-up period was
691 days. Importantly, there were no differences in annual
MMSE changes between patients receiving 200 mg/d and
those receiving 100 mg/d. The same was true in another
study where add-on of cilostazol was effective in suppress-
ing annual MMSE decline in mild dementia patients
receiving donepezil [18]. Thus, there were no differences
in annual MMSE decrease between patients receiving
200 mg/d of cilostazol and those receiving 100 mg/d. How-
ever, many previous reports showed that 100 mg/d of cilos-tazol was much safer than 200 mg/d because of fewer AEs
[31]. These data justified both the dosage and the period of
investigational treatment adopted in this trial.
The primary outcome of this trial will be measured by
MMSE as no clinical studies have so far demonstrated
the efficacy of cilostazol on cognitive function using any
other psychological battery. MMSE is the most commonly
applied test in the assessment of cognitive function in
the elderly, but other psychological tests, including CDR
and ADAS, are known to be more sensitive and more
widely used in other clinical trials. Therefore, further inves-
tigation with late phase II study may be required before
phase III trial.
In conclusion, the COMCID study is a double-blind, pla-
cebo-controlled, multicenter randomized controlled trial in-
tended to demonstrate the efficacy and safety of cilostazol in
patients withMCI. Its pleiotropic effects would not only pro-
mote Ab clearance but also retain cerebrovascular integrity
to suppress cognitive decline. The results will assess the
therapeutic potential of cilostazol, potentially opening a
new era of neurovascular therapeutic approaches for neuro-
cognitive disorders.Acknowledgments
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1. Systematic review: The authors reviewed the litera-
ture using traditional sources. Several clinical and
experimental studies have investigated the effective-
ness of cilostazol in treating Alzheimer’s disease
(AD) and mild cognitive impairment (MCI). These
relevant articles are appropriately cited.
2. Interpretation: The COMCID study is a double-
blind, placebo-controlled, randomized phase II
study that is aimed at evaluating the efficacy and
safety of cilostazol in patients with MCI.
3. Future directions: Insufficiency of vascular-mediated
amyloid-b (Ab) elimination seems to be a crucial
factor related to sporadic AD. Many researchers are
therefore now focusing on facilitating Ab clearance
and have adopted a neurovascular approach to tackle
AD and MCI. This trial will not only identify the
therapeutic potential of cilostazol for MCI patients
but also help open a new era of neurovascular treat-
ments for neurocognitive disorders.
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